Glycosylation of Secretin Peptides to Improve Drug-Like Properties

Case ID:

This invention is the development of pituitary adenylate cyclase activating peptide (PACAP) agonists for neuroprotection and antagonists for migraine.


PACAP is known as a neuronal survival factor, regulating the development, maintenance, function, and plasticity of neurons through activating PAC1, VPAC1, and VPAC2 receptors. Glycosylated PACAP analogues have been found to penetrate the blood-brain barrier (BBB) at a high rate. In addition, VPAC1/2 receptors are involved in vasodilation and may contribute to migraine attacks. It is possible to treat these migraine attacks by using PACAP antagonists.



  • A novel drug compound for the treatment of Parkinson’s disease and other neurodegenerative diseases
  • May provide a novel technique to improve BBB permeability 


  • Improves BBB permeability 
  • Possible treatment of migraines
  • Accessing the central nervous system through the BBB may provide better treatment options

Status: issued U.S. patent #10,858,410

Patent Information:
Contact For More Information:
Laura Silva
Sr. Licensing Manager, COS
The University of Arizona
Lead Inventor(s):
Robin Polt
Evan Jones
Bobbi Anglin
Michael Heien
John Streicher